PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference
January 05 2022 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies based on
the Company’s proprietary Versamune® T-cell activating technology,
today announced that its management will present at the H.C.
Wainwright Bioconnect Virtual Conference.
The presentation will provide an update on the
three ongoing PDS0101 Phase 2 clinical trials. The talk will also
provide updates on the progression of two other investigational
pipeline products PDS0102 (Versamune®-TARP) and PDS0103
(Versamune®-MUC1) into human clinical trials. The conference is
taking place virtually from January 10 - 13, 2022.
A pre-recorded presentation will be available on
Monday, January 10th at 7:00 am Eastern Time. Investors can
register for the conference HERE.
Following the conference, a webcast replay of
the presentation will be available on the Investor section of the
company’s website, PDS Biotechnology.
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of cancer immunotherapies based on the Company’s
proprietary Versamune® T-cell activating technology platform. Our
Versamune®-based products have demonstrated the potential to
overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent
polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.
PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the
immune system to better recognize diseased cells and effectively
attack and destroy them. The Company’s pipeline products
address various cancers including breast, colon, lung, prostate and
ovarian cancers. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024